In Ovo Telmisartan Exposure and Developmental Consequences in Embryonic Life Stage of Gallus gallus
Congenital Anomalies · 2026-01 · 66 (1)
DOI: 10.1002/cga.70080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Congenital Anomalies, online erschienen am 29.09.2026. Verfasst von Mriganka Das und 3 weiteren Autor:innen. Beteiligte Einrichtung: Developmental Biology Research Unit, Department of Zoology, Visva-Bharati, Santiniketan, West Bengal, India. Hauptthemen laut MEDLINE: Telmisartan, Embryonic Development, Angiotensin II Type 1 Receptor Blockers, Benzimidazoles. Die Arbeit nennt 64 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, Department of Science and Technology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Telmisartan, an antihypertensive drug, lowers blood pressure by blocking the angiotensin‐II receptor subtype‐1 (AT1). A few sporadic case studies reported adverse fetal effects of telmisartan in humans. Moreover, there is a scarcity of information from animal trials to assess its teratogenic potential. The purpose of this study is to assess the potential effects of telmisartan on embryonic development in chicks as a model. The drug was prepared in a sterile 0.9% normal saline solution (NSS) vehicle, and four different dosages of 0.0625, 0.125, 0.25, and 0.50 mg/egg were administered to the blastodiscs on each of the Hamburger and Hamilton (HH) stages 4, 7, 9, and 12. The developmental outcomes of all experimental embryos were assessed at HH stages 14, 19, and 24. Exposure to telmisartan resulted in syndromic development characterized by a wide range of morphological deformities in neural, optic, and otic development; abnormal looping of the heart; delayed angiogenesis; somitic anomalies; and incomplete body flexure. Telmisartan affected heart rate, body length, somite numbers, and area vasculosa in a dose‐ and stage‐dependent manner. The results of this animal model experiment will help assess the teratogenic potential of telmisartan and will serve as a foundation for future research to uncover the mechanisms underlying telmisartan‐induced developmental assault.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Developmental Biology Research Unit, Department of Zoology, Visva-Bharati, Santiniketan, West Bengal, India.
ORCID-Profile: Mriganka Das, Samar Kumar Saha
Förderung
- Council of Scientific and Industrial Research, India
- Department of Science and Technology, Ministry of Science and Technology, India
Zitieren
APA
Das, M., Mukherjee, D., Mondal, S., & Saha, S. K. (2026). In Ovo Telmisartan Exposure and Developmental Consequences in Embryonic Life Stage of Gallus gallus. Congenital Anomalies, 66(1). https://doi.org/10.1002/cga.70080
Vancouver
Das M, Mukherjee D, Mondal S, Saha SK. In Ovo Telmisartan Exposure and Developmental Consequences in Embryonic Life Stage of Gallus gallus. Congenital Anomalies. 2026;66(1). doi:10.1002/cga.70080
BibTeX
@article{Das2026,
author = {Das, Mriganka and Mukherjee, Dutimoy and Mondal, Supriya and Saha, Samar Kumar},
title = {In Ovo Telmisartan Exposure and Developmental Consequences in Embryonic Life Stage of Gallus gallus},
journal = {Congenital Anomalies},
year = {2026},
volume = {66},
number = {1},
doi = {10.1002/cga.70080}
}
EUVIMED